Biotechnology company Audentes Therapeutics Inc (Nasdaq:BOLD) said on Friday that its board of directors' compensation committee has awarded stock options to ten new individuals hired in January 2019 in accordance with Nasdaq Listing Rule 5635(c)(4).

In the aggregate, the employees received options to purchase 49,300 shares of common stock from the company.

The company added that the options have an exercise price of USD24.93 per share, which is equal to the closing price of its common stock on 5 February 2019.

Subject to each such employee's continued employment with the company on such vesting dates, one-fourth of the shares underlying each employee's option will vest on the one year anniversary of his or her date of hire and thereafter 1/48th of the shares underlying each employee's option will vest monthly, such that the shares underlying the option granted to each employee will be fully vested on the fourth anniversary of his or her date of hire, in each case.